financetom
Business
financetom
/
Business
/
Wealth manager Truxton's Q3 profit rises on higher loan growth
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Wealth manager Truxton's Q3 profit rises on higher loan growth
Oct 23, 2025 6:32 AM

Overview

* Truxton Q3 net income rises 23% yr/yr, reflecting strong earnings growth

* Company's Q3 net interest margin declines from prior qtr but improves yr/yr

* Truxton's Q3 deposits increase 11% from prior qtr, up 30% yr/yr

Outlook

* Truxton did not provide specific guidance for future quarters or the full year

Result Drivers

* DEPOSIT GROWTH - Truxton's deposits increased 11% from the prior quarter and 30% year-over-year, supported by superior deposit operations and wholesale funding sources

* WEALTH MANAGEMENT REVENUE - Wealth revenue rose 8% from the previous quarter and 7% year-over-year, contributing to non-interest income growth

* LOAN GROWTH - Loans increased 4% from the previous quarter and 8% year-over-year, aiding interest income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net $5.60

Income mln

Q3 Net 2.82%

Interest

Margin

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing
Sarepta Therapeutics Insider Sold Shares Worth $1,848,795, According to a Recent SEC Filing
Mar 12, 2024
09:20 AM EDT, 03/12/2024 (MT Newswires) -- Hans Lennart Rudolf Wigzell, Director, on March 08, 2024, sold 15,000 shares in Sarepta Therapeutics ( SRPT ) for $1,848,795. Following the Form 4 filing with the SEC, Wigzell has control over a total of 22,840 shares of the company, with 22,840 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/873303/000095017024029536/xslF345X03/ownership.xml Price: 123, Change: +1.42, Percent...
--Apple to Allow Developers to Distribute Apps in EU Directly From Their Websites
--Apple to Allow Developers to Distribute Apps in EU Directly From Their Websites
Mar 12, 2024
09:21 AM EDT, 03/12/2024 (MT Newswires) -- Price: 172.98, Change: +0.23, Percent Change: +0.13 ...
Why On Holding Shares Are Plunging Today
Why On Holding Shares Are Plunging Today
Mar 12, 2024
On Holding AG ( ONON ) shares are trading lower after it reported fourth-quarter FY23 earnings. The company reported fourth-quarter FY23 sales growth of 21.9% year-on-year to CHF 447.1 million ($504.23 million), missing the analyst consensus estimate of $510.19 million. Adjusted diluted EPS for Class A shares decreased to CHF (0.05) ($(0.06)) from CHF 0.02 in the prior year, missing the consensus estimate...
Pfizer's Phase 3 Study of Adcetris Demonstrates Significant Improvement in Overall Survival
Pfizer's Phase 3 Study of Adcetris Demonstrates Significant Improvement in Overall Survival
Mar 12, 2024
09:20 AM EDT, 03/12/2024 (MT Newswires) -- Pfizer ( PFE ) said Tuesday that a phase 3 study of Adcetris in combination with lenalidomide and rituximab to treat patients with relapsed/refractory diffuse large B-cell lymphoma demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival. There were also positive outcomes in secondary endpoints that included...
Copyright 2023-2026 - www.financetom.com All Rights Reserved